Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system

Mediterranean Journal of Rheumatology

ARTICLE

Charalambos Skarlis¹  Eleni Palli¹  Andrianos Nezos¹  Michail Koutsilieris¹  Clio P. Mavragani¹ 

[1] Department of Physiology,  School of Medicine, National University of Athens

关键词: RANKL;    RANK;    osteoprotegerin (OPG);    primary Sjögren’s syndrome;    autoimmunity;    autoimmune diseases;    osteoporosis;   

DOI  :  10.31138/mjr.29.4.224

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

Primary Sjögren’s syndrome (pSS) is a common chronic autoimmune disease affecting 0.5-4.8% of the population. It is characterized by lymphocytic infiltration of exocrine glands - mainly salivary and lacrimal - resulting in oral and ocular dryness, although any organ system can virtually be affected. Among all autoimmune diseases, pSS has the highest risk for development of non-Hodgkin’s lymphoma (NHL) and approximately 10% of patients with SS associated with increased risk for B-cell lymphoma development and high mortality rates. In pSS there are various systemic manifestations; such as arthritis, rashes, Raynaud’s phenomenon, peripheral neuropathy and glomerulonephritis.1,2 While over the past few years, the importance of coexistence in the context of systemic autoimmune diseases such as subclinical atherosclerosis and osteoporosis has been extensively studied in pSS, data on the incidence and underlying pathophysiological mechanisms of osteopenia/osteoporosis are limited.

【 授权许可】

CC BY-NC